Our Pricing

When you buy Wegovy injection doses online UK through Cured Pharmacy, you're accessing genuine semaglutide weight loss treatment from £79.00 with full clinical support from our UK-registered prescribers. Each Wegovy pen delivers a precise weekly dose designed to help you achieve sustainable weight loss under medical supervision.

Understanding Wegovy Injection Doses and Titration Schedule

Wegovy (semaglutide 2.4mg) follows a carefully structured dose escalation programme designed to minimise gastrointestinal side effects whilst optimising weight loss outcomes. The treatment begins at 0.25mg weekly for the first month, gradually increasing over 16 weeks to the maintenance dose of 2.4mg weekly [1].

This titration schedule isn't arbitrary — clinical data from the STEP trials demonstrated that gradual dose escalation significantly reduces the incidence of nausea and vomiting compared to starting at higher doses [1]. Your UK prescriber will determine the appropriate starting dose based on your medical history and current medications.

Each Wegovy pen is pre-filled and single-use, containing four doses for one month of treatment. The complete dose progression follows this MHRA-approved schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), and 2.4mg (week 17 onwards) [2].

What Happens If You Miss a Dose?

If you miss your weekly Wegovy injection and it's been less than 5 days since your scheduled dose, administer it as soon as you remember. If more than 5 days have passed, skip that dose entirely and resume your normal schedule with the next planned injection [2]. Never double up doses to compensate for a missed injection, as this increases the risk of gastrointestinal adverse effects.

How Wegovy Semaglutide Works for Weight Loss

Semaglutide, the active pharmaceutical ingredient in Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone your body produces after eating. By activating GLP-1 receptors in the brain, pancreas, and digestive system, Wegovy helps regulate appetite, slow gastric emptying, and improve glycaemic control [1].

In the landmark STEP 1 trial involving 1,961 adults with obesity, participants receiving semaglutide 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo — all whilst following a reduced-calorie diet and increased physical activity programme [1]. These results represented the most significant weight loss outcomes seen in any GLP-1 trial at the time of publication.

The medication works through multiple complementary mechanisms: reducing hunger signals in the hypothalamus, delaying how quickly food leaves your stomach (increasing satiety), and modestly improving insulin sensitivity. This multi-pathway approach explains why Wegovy consistently outperforms older weight loss medications in head-to-head trials [3].

Wegovy Injection Doses: Who Can Use Them in the UK?

Wegovy is licensed by the MHRA for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea [2]. Your UK prescriber will calculate your BMI and review your medical history during the online consultation to determine eligibility.

The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. You should inform your prescriber if you have a history of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, or renal impairment, as these conditions require careful clinical assessment before starting treatment [2].

Wegovy is not recommended during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception during treatment and for two months after discontinuation, as weight loss itself may increase fertility and semaglutide takes approximately five weeks to clear from your system [2].

Age and Medical Eligibility

Wegovy is currently licensed for adults aged 18 years and older in the UK. Whilst clinical trials have evaluated semaglutide in adolescents aged 12-17 years, this indication has not yet been widely adopted in UK clinical practice. Your prescriber will assess whether Wegovy represents the most appropriate treatment option based on your individual circumstances, previous weight loss attempts, and overall health status.

Common Side Effects and How to Manage Them

The most frequently reported adverse effects with Wegovy are gastrointestinal in nature, including nausea (44% of patients), diarrhoea (30%), vomiting (24%), and constipation (24%) in clinical trials [1]. These symptoms typically emerge during dose escalation and tend to diminish over time as your body adapts to the medication.

Practical strategies to minimise GI side effects include eating smaller, more frequent meals rather than large portions, avoiding high-fat and heavily processed foods, staying well-hydrated, and taking your injection on the same day each week. If nausea becomes troublesome, your prescriber may recommend temporarily maintaining your current dose for an additional week before continuing the escalation schedule [2].

Less common but more serious adverse effects include acute pancreatitis (occurring in approximately 0.2% of patients), gallbladder disease, and hypoglycaemia when used alongside other glucose-lowering medications [1][2]. Contact your GP or NHS 111 immediately if you experience severe persistent abdominal pain, as this may indicate pancreatitis requiring urgent medical assessment.

Buy Wegovy Injection Doses Online UK: The Cured Pharmacy Process

Purchasing Wegovy through Cured Pharmacy begins with a free online clinical consultation that takes under three minutes to complete. You'll answer questions about your medical history, current medications, weight loss goals, and any contraindications that might affect prescribing decisions. This assessment is reviewed by a UK-registered prescriber (not an AI system or overseas clinician) who will determine whether Wegovy is clinically appropriate for you.

If approved, your prescription is sent electronically to our UK-registered pharmacy (GPhC 9012511), where superintendent pharmacist Tarun Kumar GPhC 2233073 and his team dispense your medication. We source all Wegovy pens directly from UK-licensed wholesalers — never grey market imports — ensuring full product traceability and compliance with MHRA regulations.

Your Wegovy injection doses arrive in 100% discreet packaging with no external branding or pharmacy labels visible. We offer flexible delivery options including next-day courier service, and our clinical team remains available by phone (+44 116 4646009) throughout your treatment journey should you have questions about dosing, side effects, or ongoing management.

Transparent Pricing Before Consultation

Unlike some online services that only reveal costs after consultation, Cured Pharmacy displays upfront pricing of £79.00 before you begin your assessment. This transparent approach means no unexpected charges or hidden consultation fees — what you see is what you pay. We guarantee the lowest prices in the UK for genuine licensed Wegovy, and our pricing includes both the medication and prescriber review.

Maximising Weight Loss Results with Wegovy Injections

Whilst Wegovy produces significant weight loss independently, clinical trial data consistently shows that combining the medication with lifestyle modifications produces superior outcomes. The STEP 1 protocol included a 500 kcal/day deficit diet and 150 minutes of weekly physical activity, creating a comprehensive weight management programme [1].

Your prescriber may recommend working with a registered dietitian or following structured programmes like the NHS-endorsed low-calorie diet plans. Behavioural support — whether through apps, support groups, or counselling — has been shown to improve medication adherence and long-term weight maintenance after treatment discontinuation [3].

Most patients begin noticing appetite reduction within the first two weeks of treatment, with measurable weight loss typically evident by week 4-8. The STEP trials demonstrated that patients who hadn't achieved at least 5% weight loss by week 16 were unlikely to reach clinically meaningful outcomes at the maintenance dose, helping prescribers identify non-responders early [1]. Your UK clinical team will monitor your progress and adjust your treatment plan accordingly.

After reaching your goal weight, your prescriber will discuss maintenance strategies. Some patients continue Wegovy long-term to sustain weight loss, whilst others transition to lifestyle management alone. Clinical data shows that discontinuing semaglutide typically results in gradual weight regain, with patients regaining approximately two-thirds of lost weight within one year of stopping treatment [4].

Realistic Weight Loss Expectations

Individual results vary considerably based on starting weight, adherence, lifestyle factors, and metabolic differences. Whilst trial averages show 14.9% body weight reduction, some patients lose significantly more and others less [1]. Your prescriber will help establish realistic, personalised goals that account for your unique circumstances and medical history.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799
3. Rubino, D., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., Rudofsky, G., Tadayon, S., Wadden, T. A., & Dicker, D. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
4. Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., Wadden, T. A., Wharton, S., Yokote, K., Kushner, R. F., & STEP 1 Study Group. (2022). Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 24(8), 1553–1564. https://doi.org/10.1111/dom.14725

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.